Baird Reiterates Buy Rating on Ocular Therapeutix, Inc.

Baird has reiterated its buy rating on Ocular Therapeutix, Inc. (NasdaqGM: OCUL) with a price target of $30. This update was made on June 18, 2026, as the stock trades near $9.64.

Other Institutional Activity in Ocular Therapeutix

Several institutional investors have adjusted their positions in Ocular Therapeutix. FMR LLC increased its holdings by 868,159 shares, bringing its total to approximately 32.65 million shares worth about $276.58 million. DEEP TRACK CAPITAL, LP significantly boosted its stake by 11.62 million shares, now holding around 19.69 million shares valued at $166.74 million. BLACKROCK, INC. added 530,537 shares, ending with 16.13 million shares worth approximately $136.65 million. AVORO CAPITAL ADVISORS LLC also increased its position by 1.54 million shares, holding 12.32 million shares valued at $104.31 million. SUMMER ROAD LLC added 771,270 shares, totaling about 11.88 million shares worth $100.62 million.

Ocular Therapeutix, Inc. Stock Down 2.2%

Shares of Ocular Therapeutix, Inc. trade around $9.64 on the NasdaqGM. The company has a market capitalization of roughly $2.11 billion. Its stock has shown a 52-week low of $6.23 and a high of $16.44. The 50-day moving average is $9.00, while the 200-day moving average is $10.53. Ocular Therapeutix has a current ratio of 14.81 and a quick ratio of 14.49, with a debt-to-equity ratio of 13.66.

Recent Earnings

Ocular Therapeutix reported revenue of $52.04 million, showing slight growth of 0.8%. However, the company is not currently profitable, with no meaningful P/E ratio due to a negative EPS of -$1.44. The net margin stands at 0%, and return on equity is -68.55%. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at Ocular Therapeutix, Inc.

Recent insider activity includes the purchase of shares by several insiders on June 10, 2026. Adrienne Graves acquired 44,000 shares, while Jason Shand Robins, the Chief Financial Officer, bought 14,024 shares. Seung Suh Hong and Richard Lindstrom each acquired 14,000 shares. These transactions were not part of a pre-planned 10b5-1 trading plan.

Analysts Set New Price Targets

On June 18, 2026, Baird maintained its buy rating on Ocular Therapeutix with a price target of $30. RBC Capital also reiterated a buy rating with a $30 target on May 6, 2026. HC Wainwright & Co. and Chardan Capital have maintained buy ratings with targets of $21. The consensus among 11 analysts is a strong buy, with a mean price target of $26.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts. It focuses on developing and commercializing therapies for eye diseases using its hydrogel-based technology. The company markets DEXTENZA, an insert for post-surgical ocular inflammation, and is developing other treatments like AXPAXLI and OTX-TIC for retinal diseases and glaucoma. Founded in 2006, it employs about 325 people.

Bottom Line

Baird's reiteration of a buy rating with a $30 target highlights continued confidence in Ocular Therapeutix's potential. Investors and analysts closely watch the company's progress in developing eye disease treatments. As always, keep in mind that analyst ratings are opinions and past filings may not reflect current positions.